Treatment of Asthma: The long-acting beta-2-agonists
- PDF / 15,909,701 Bytes
- 189 Pages / 396.85 x 612.283 pts Page_size
- 39 Downloads / 165 Views
SpringerWienN ewYork
Prof. Dr. med. Friedrich Kummer
2. Medizinische Abteilung mit Lungenkrankheiten und Tuberkulose, Wilhelminenspital, Wien, Osterreich
This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying machines or similar means, and storage in data banks. Product Liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of specific statements that such names are exempt from the relevant protective laws and regulations and therefore free for general use. © 1998 Springer-VerlaglWien Typesetting: H. Meszarics· Satz & Layout· A-1200 Wien Graphic design: Ecke Bonk Printed on acid-free and chlorine-free bleached paper SPIN: 10675873
With 35 Figures Library of Congress Cataloging-in-Publication Data Treatment of asthma: the long-acting beta-2-agonists / Friedrich Kummer (Hrsg.) p.cm. Includes bibliographical references and index. ISBN -l3 :978-3-211-83l24-3 e- ISBN -l3 :978-3-7091-75l3-2 DOl: 10.1007/978-3-7091-75l3-2 1. Asthma - Chemotherapy. 2. Adrenergic beta agonists. I. Kummer, Friedrich.
[DNLM: I. Asthma - drug therapy. ,2. Adrenergic beta-Agonists - therapeutic use. 3. Adrenergic beta-Agonists - pharmacology. WF 553 T784 1998] RC591.T74 1998 616.2'38061 - dc21
ISBN -13 :978-3-211-83124-3
Preface The traditional Vienna Asthma Forum was held in early June 1996 and was the 6th in a biennial mode within 10 years. This time it was dedicated to the long-acting beta-2-agonists, which were registered (or just about to be) in most European countries. The introduction of this therapeutic principle into routine praxis of asthma therapy was so successful that a closer view on the subject from a scientific point was warranted. Salmeterol, shortly afterwards formoterol are the drugs available for the inhalative route, while bambuterol serves as an oral agent. The scientists particularly involved in the design and pharmacokinetics of these drugs were invited, and we were lucky that Malcolm Johnson (Glaxo), Leif Svensson (Astra) and Gary Anderson (CibaGeigy) delivered fascinating contributions. However, drug therapy of this kind can only be effective if based on a thorough understanding of the molecular biology of cells and receptors, which was superbly covered by Sheila Collins (Durham) and Ian M. Adcock (London). The pediatric indications for beta-2-agonists were commented by Manfred G6tz (Vienna), and a large spectrum of clinical studies, reported by G. Boyd (Glasgow), A.P. Greening (Edinburgh), M. Rudolph (Middlesex), O. Selroos (Lund) and B. Villiger (Davos) evoked the mutual acid interest of speakers and audience, who engaged in vivid, high quality disc
Data Loading...
